1. Home
  2. OCUL
  3. OCUL News

Latest Ocular Therapeutix Inc. (OCUL) News on July 27, 2024

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

8 days ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing
OCUL

Simply Wall St.

14 days ago

The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
OCUL

GlobeNewswire

17 days ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

18 days ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCUL

MT Newswires

a month ago

Ocular Therapeutix Shares Rise After TD Cowen Upgrades Rating, Increases Price Target

OCUL

MT Newswires

a month ago

TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7

OCUL

MT Newswires

a month ago

Sector Update: Health Care Stocks Decrease Late Afternoon

OCUL

MT Newswires

a month ago

Ocular Therapeutix Shares Rise Following Clinical Development Progress Report

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
OCUL

GlobeNewswire

a month ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued
OCUL

Simply Wall St.

2 months ago

An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued

Ocular Therapeutix® to Host Investor Day on June 13, 2024
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCUL

MT Newswires

2 months ago

Ocular Therapeutix Cutting 13% of Workforce

OCUL

MT Newswires

2 months ago

Piper Sandler Starts Ocular Therapeutix With Overweight Rating, $15 Price Target

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
OCUL

GuruFocus.com

3 months ago

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings

OCUL

Associated Press Finance

3 months ago

Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix™ Reports First Quarter 2024 Results
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

2 Small-Cap Growth Stocks With Room to Run
OCUL

Motley Fool

3 months ago

2 Small-Cap Growth Stocks With Room to Run

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
OCUL

Benzinga

3 months ago

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
OCUL

Zacks

4 months ago

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

OCUL

Thomson Reuters StreetEvents

4 months ago

Q4 2023 Clearside Biomedical Inc Earnings Call

Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
OCUL

Zacks

4 months ago

Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet

Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts
OCUL

GuruFocus.com

5 months ago

Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
OCUL

Zacks

5 months ago

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

OCUL

Associated Press Finance

5 months ago

Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors
OCUL

Barrons.com

5 months ago

Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors

Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?
OCUL

Zacks

5 months ago

Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?

Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice
OCUL

Zacks

5 months ago

Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice

Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
OCUL

Zacks

5 months ago

Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

3 Stocks to Buy That Are Up 100% or More in 2024
OCUL

InvestorPlace

5 months ago

3 Stocks to Buy That Are Up 100% or More in 2024

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade
OCUL

Zacks

5 months ago

Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
OCUL

PR Newswire

5 months ago

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?
OCUL

Zacks

5 months ago

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?

Bel Fuse (BELFB) Stock Declines While Market Improves: Some Information for Investors
OCUL

Zacks

6 months ago

Bel Fuse (BELFB) Stock Declines While Market Improves: Some Information for Investors

PIEDMONT OFFICE REALTY TRUST DECLARES FIRST QUARTER DIVIDEND
OCUL

GlobeNewswire

6 months ago

PIEDMONT OFFICE REALTY TRUST DECLARES FIRST QUARTER DIVIDEND

Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?
OCUL

Zacks

6 months ago

Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?

Enterprise Bancorp Inc (EBTC) Reports Decline in Quarterly Net Income Amidst Rising Interest Rates
OCUL

GuruFocus.com

6 months ago

Enterprise Bancorp Inc (EBTC) Reports Decline in Quarterly Net Income Amidst Rising Interest Rates

Why Fisker Stock Dived by Almost 9% Today
OCUL

Motley Fool

6 months ago

Why Fisker Stock Dived by Almost 9% Today

Is Navigator Holdings (NVGS) Outperforming Other Transportation Stocks This Year?
OCUL

Zacks

6 months ago

Is Navigator Holdings (NVGS) Outperforming Other Transportation Stocks This Year?

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
OCUL

Benzinga

6 months ago

Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?

OCUL

Reuters

6 months ago

CORRECTED-SEC probes B. Riley deals with client tied to failed hedge fund - Bloomberg News

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 36% Undervaluation?
OCUL

Simply Wall St.

6 months ago

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 36% Undervaluation?

One Sprott Insider Raised Their Stake In The Previous Year
OCUL

Simply Wall St.

6 months ago

One Sprott Insider Raised Their Stake In The Previous Year

Bel Announces a New President of the Power and Protection Segment
OCUL

GlobeNewswire

6 months ago

Bel Announces a New President of the Power and Protection Segment

Sidoti Events, LLC's Virtual January Micro-Cap Conference
OCUL

ACCESSWIRE

6 months ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Cerence and Škoda Elevate the In-Vehicle Experience with Cerence Chat Pro
OCUL

GlobeNewswire

6 months ago

Cerence and Škoda Elevate the In-Vehicle Experience with Cerence Chat Pro

AMC Networks (NASDAQ:AMCX) Could Be Struggling To Allocate Capital
OCUL

Simply Wall St.

6 months ago

AMC Networks (NASDAQ:AMCX) Could Be Struggling To Allocate Capital

Here’s Why B Riley Financial (RILY) Fell in Q4
OCUL

Insider Monkey

6 months ago

Here’s Why B Riley Financial (RILY) Fell in Q4

Nayax Opens Additional Technical Support Center
OCUL

GlobeNewswire

6 months ago

Nayax Opens Additional Technical Support Center

Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick
OCUL

Zacks

7 months ago

Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick

Great Wall Motor Selects Cerence to Power In-Car Experience as Automaker Expands Globally
OCUL

GlobeNewswire

7 months ago

Great Wall Motor Selects Cerence to Power In-Car Experience as Automaker Expands Globally

SAVE THE DATE: NOVAGOLD 2023 Year-End Financial Results Release, Conference Call and Video Webcast
OCUL

GlobeNewswire

7 months ago

SAVE THE DATE: NOVAGOLD 2023 Year-End Financial Results Release, Conference Call and Video Webcast

Income on Autopilot: 7 Monthly Dividend Stocks to Buy for Stability
OCUL

InvestorPlace

7 months ago

Income on Autopilot: 7 Monthly Dividend Stocks to Buy for Stability

ECARX Announces Board Changes
OCUL

GlobeNewswire

7 months ago

ECARX Announces Board Changes

Capital Product Partners L.P. Announces the Successful Delivery of the LNG Carrier ‘Axios II’
OCUL

GlobeNewswire

7 months ago

Capital Product Partners L.P. Announces the Successful Delivery of the LNG Carrier ‘Axios II’

Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
OCUL

Motley Fool

7 months ago

Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024

OCUL

Reuters

7 months ago

UPDATE 2-Iberdrola's Avangrid terminates $8.3 bln deal to buy PNM Resources

Companies Like LanzaTech Global (NASDAQ:LNZA) Are In A Position To Invest In Growth
OCUL

Simply Wall St.

7 months ago

Companies Like LanzaTech Global (NASDAQ:LNZA) Are In A Position To Invest In Growth

Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company
OCUL

Simply Wall St.

7 months ago

Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company

7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World
OCUL

InvestorPlace

7 months ago

7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World

3 Red Hot Megatrends to Invest in for 2024
OCUL

Motley Fool

7 months ago

3 Red Hot Megatrends to Invest in for 2024

Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference
OCUL

GlobeNewswire

7 months ago

Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 72% Price Boost Is Out Of Tune With Revenues
OCUL

Simply Wall St.

7 months ago

Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 72% Price Boost Is Out Of Tune With Revenues

Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
OCUL

Zacks

7 months ago

Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade
OCUL

Zacks

7 months ago

Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade

10 Stocks with 50% Upside Potential According to Analysts
OCUL

Insider Monkey

8 months ago

10 Stocks with 50% Upside Potential According to Analysts

Vivid Seats Announces Pricing of Secondary Offering and Repurchase of Class A Common Stock
OCUL

GlobeNewswire

8 months ago

Vivid Seats Announces Pricing of Secondary Offering and Repurchase of Class A Common Stock

Does the New Anti-Obesity Medicine Affect Treace Medical Concepts (TMCI)?
OCUL

Insider Monkey

8 months ago

Does the New Anti-Obesity Medicine Affect Treace Medical Concepts (TMCI)?

Are Retail-Wholesale Stocks Lagging ACV Auctions (ACVA) This Year?
OCUL

Zacks

8 months ago

Are Retail-Wholesale Stocks Lagging ACV Auctions (ACVA) This Year?

OCUL

Associated Press Finance

9 months ago

Seneca Foods: Fiscal Q2 Earnings Snapshot

Seneca Foods Reports Sales and Earnings for the Quarter and Six Months Ended September 30, 2023
OCUL

GlobeNewswire

9 months ago

Seneca Foods Reports Sales and Earnings for the Quarter and Six Months Ended September 30, 2023

MRC Global Inc. (NYSE:MRC) Q3 2023 Earnings Call Transcript
OCUL

Insider Monkey

9 months ago

MRC Global Inc. (NYSE:MRC) Q3 2023 Earnings Call Transcript

OCUL

Thomson Reuters StreetEvents

9 months ago

Q1 2024 InnovAge Holding Corp Earnings Call

InnovAge Holding Corp. (INNV) Reports Q1 Loss, Tops Revenue Estimates
OCUL

Zacks

9 months ago

InnovAge Holding Corp. (INNV) Reports Q1 Loss, Tops Revenue Estimates

InnovAge Announces Financial Results For The Fiscal First Quarter Ended September 30, 2023
OCUL

GlobeNewswire

9 months ago

InnovAge Announces Financial Results For The Fiscal First Quarter Ended September 30, 2023

OCUL

PR Newswire

9 months ago

BRISTOW GROUP REPORTS THIRD QUARTER 2023 RESULTS

Share on Social Networks: